Valneva (VALN) has released an update.
Valneva SE has announced a significant advancement with the European Medicines Agency’s positive opinion on its chikungunya vaccine, IXCHIQ®, which may become the first such vaccine approved in the EU. A final decision by the European Commission is expected in Q3 2024, following the recent U.S. approval. The vaccine shows a high seroresponse rate and is part of Valneva’s broader effort to address infectious diseases with unmet medical needs.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
